Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer

Table 1

The detailed demographic and clinical characteristics of study population.

	Survival status			-value
	Alive	Cause-specific death	Other-specific death
N	582	538	180
Age(years)	72.0 (66.0–77.0)	74.0 (68.0–80.0)	73.0 (66.8–80.0)	<0.001
Age				0.062
<65 years	120 (20.6%)	82 (15.2%)	31 (17.2%)
≥65 years	462 (79.4%)	456 (84.8%)	149 (82.8%)
Sex				<0.001
Female	373 (64.1%)	281 (52.2%)	103 (57.2%)
Male	209 (35.9%)	257 (47.8%)	77 (42.8%)
Marital status				0.009
Unmarried	250 (43.0%)	264 (49.1%)	77 (42.8%)
Married	332 (57.0%)	274 (50.9%)	103 (57.2%)
Race				0.405
Other	37 (6.4%)	22 (4.1%)	7 (3.9%)
Black	74 (12.7%)	77 (14.3%)	24 (13.3%)
White	471 (80.9%)	439 (81.6%)	149 (82.8%)
Laterality (SPLC)				0.672
Left	265 (45.5%)	231 (42.9%)	81 (45.0%)
Right	317 (54.5%)	307 (57.1%)	99 (55.0%)
Primary site (SPLC)				0.006
Main	7 (1.2%)	25 (4.6%)	2 (1.1%)
Upper	302 (51.9%)	292 (54.3%)	92 (51.1%)
Middle	49 (8.4%)	35 (6.5%)	17 (9.4%)
Low	224 (38.5%)	186 (34.6%)	69 (38.3%)
Histology (SPLC)				<0.001
Small cell carcinoma	17 (2.9%)	92 (17.1%)	10 (5.6%)
Large cell carcinoma	16 (2.7%)	21 (3.9%)	6 (3.3%)
Squamous cell carcinoma	116 (19.9%)	145 (27.0%)	58 (32.2%)
Adenocarcinoma	381 (65.5%)	243 (45.2%)	95 (52.8%)
Other	52 (8.9%)	37 (6.9%)	11 (6.1%)
Tumor size (SPLC)				<0.001
≤2 cm	368 (63.2%)	192 (35.7%)	89 (49.4%)
>2 cm	214 (36.8%)	346 (64.3%)	91 (50.6%)
AJCC N, 6th ed (SPLC)				<0.001
N0	536 (92.1%)	333 (61.9%)	145 (80.6%)
N1	13 (2.2%)	40 (7.4%)	14 (7.8%)
N2	25 (4.3%)	121 (22.5%)	19 (10.6%)
N3	8 (1.4%)	44 (8.2%)	2 (1.1%)
AJCC M, 6th ed(SPLC)				<0.001
M0	555 (95.4%)	405 (75.3%)	157 (87.2%)
M1	27 (4.6%)	133 (24.7%)	23 (12.8%)
AJCC T, 6th ed(SPLC)				<0.001
T1	386 (66.3%)	229 (42.6%)	98 (54.4%)
T2	103 (17.7%)	160 (29.7%)	43 (23.9%)
T3	11 (1.9%)	26 (4.8%)	5 (2.8%)
T4	82 (14.1%)	123 (22.9%)	34 (18.9%)
Tumor stage (SPLC)				<0.001
I	450 (77.3%)	246 (45.7%)	115 (63.9%)
II	24 (4.1%)	29 (5.4%)	14 (7.8%)
III	81 (13.9%)	130 (24.2%)	28 (15.6%)
IV	27 (4.6%)	133 (24.7%)	23 (12.8%)
SEER combined summary Stage (SPLC)				<0.001
Localized	403 (69.2%)	220 (40.9%)	99 (55.0%)
Regional	140 (24.1%)	150 (27.9%)	49 (27.2%)
Distant	39 (6.7%)	168 (31.2%)	32 (17.8%)
Chemotherapy (SPLC)				<0.001
Yes	100 (17.2%)	201 (37.4%)	42 (23.3%)
No/unknown	482 (82.8%)	337 (62.6%)	138 (76.7%)
Radiation/surgery (SPLC)				<0.001
Surgery alone	315 (54.1%)	134 (24.9%)	66 (36.7%)
Radiation	173 (29.7%)	158 (29.4%)	63 (35.0%)
Radiation + surgery	46 (7.9%)	65 (12.1%)	16 (8.9%)
No	48 (8.2%)	181 (33.6%)	35 (19.4%)
Primary site (IPLC)				0.004
Main	2 (0.3%)	10 (1.9%)	1 (0.6%)
Upper	364 (62.5%)	345 (64.1%)	105 (58.3%)
Middle	33 (5.7%)	51 (9.5%)	13 (7.2%)
Low	183 (31.4%)	132 (24.5%)	61 (33.9%)
Laterality (IPLC)				0.539
Left	268 (46.0%)	236 (43.9%)	75 (41.7%)
Right	314 (54.0%)	302 (56.1%)	105 (58.3%)
Histology (IPLC)				<0.001
Small cell carcinoma	29 (5.0%)	27 (5.0%)	5 (2.8%)
Large cell carcinoma	24 (4.1%)	30 (5.6%)	17 (9.4%)
Squamous cell carcinoma	108 (18.6%)	162 (30.1%)	52 (28.9%)
Adenocarcinoma	367 (63.1%)	269 (50.0%)	93 (51.7%)
Other	54 (9.3%)	50 (9.3%)	13 (7.2%)
Histology of IPLC and SPLC				<0.001
Different	410 (70.4%)	433 (80.5%)	135 (75.0%)
Same	172 (29.6%)	105 (19.5%)	45 (25.0%)
Interval time of IPLC and SPLC(months)	70.0 (58.0–90.0)	68.0 (55.2–83.8)	67.0 (56.0–82.2)	0.003
Tumor stage (IPLC)				0.045
I	416 (77.0%)	382 (78.1%)	116 (69.0%)
II	29 (5.4%)	28 (5.7%)	21 (12.5%)
III	82 (15.2%)	67 (13.7%)	26 (15.5%)
IV	13 (2.4%)	12 (2.5%)	5 (3.0%)
Chemotherapy (IPLC)				0.397
Yes	149 (25.6%)	154 (28.6%)	44 (24.4%)
No/unknown	433 (74.4%)	384 (71.4%)	136 (75.6%)
Radiation/surgery (SPLC)				<0.001
Surgery alone	502 (86.3%)	414 (77.0%)	146 (81.1%)
Radiation	27 (4.6%)	65 (12.1%)	12 (6.7%)
Radiation + surgery	42 (7.2%)	45 (8.4%)	18 (10.0%)
No	11 (1.9%)	14 (2.6%)	4 (2.2%)
Follow-up time (months)	30.0 (19.0–46.0)	12.0 (5.0–24.0)	17.0 (7.0–31.2)	<0.001

Note. IPLC, initial primary lung cancer; SPLC, second primary lung cancer.